Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

From ‘Booster-For-All’ To ‘Pfizer-For-Some’: Lessons From The Third Shot Debate

Executive Summary

Biden Administration met its self-declared goal of launching a booster campaign ‘the week of September 20’ – but with a more complex messaging challenge than anyone could have wanted after US FDA authorization and CDC recommendation for a ‘booster’ dose of Pfizer/BioNTech’s COVID vaccine left considerable confusion about who should get a third shot.

You may also be interested in...



Pfizer’s Quest For COVID Vaccine Correlates Of Protection Running Into Roadblocks

Pfizer scientists said they are having trouble identifying an immune correlate of protection for the company's COVID-19 vaccine, while other scientists expressed optimism that neutralizing antibodies might eventually be able to be used as a correlate, though there were some questions raised about using them for booster decision making.

Walensky Defends Decision To Go Against Advisors On Pfizer COVID Booster Recommendation

‘If I had been in the room, I would have voted yes,’ CDC director says of ACIP. ‘This was a scientific close call. ... And that was how my recommendations came out after listening to all of their scientific deliberations.’

One Down, Two To Go: Pfizer/BioNTech Booster Decision Creates Pressure For More Extra Shot Authorizations

Inequity created by limiting the mRNA vaccine’s third dose to only those individuals who received a primary series of the same vaccine, as well as resulting operational complexities, warrant consideration of a mix-and-match approach with Moderna and J&J products, CDC advisors say; however, FDA appears most focused on vetting manufacturer-specific data on homologous boosting.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS145026

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel